"Young children have died or become seriously ill from accidental exposure to a skin patch containing fentanyl, a powerful pain reliever. As a result of this, the Food and Drug Administration (FDA) is issuing a Drug Safety Communication to warn pa"...
- Patient Information:
Details with Side Effects
NUBAIN (nalbuphine hydrochloride) is a potent analgesic. Its analgesic potency is essentially equivalent to that of morphine on a milligram basis. Receptor studies show that NUBAIN (nalbuphine hydrochloride) binds to mu, kappa, and delta receptors, but not to sigma receptors. NUBAIN (nalbuphine hydrochloride) is primarily a kappa agonist/partial mu antagonist analgesic.
The onset of action of NUBAIN (nalbuphine hydrochloride) occurs within 2 to 3 minutes after intravenous administration, and in less than 15 minutes following subcutaneous or intramuscular injection. The plasma half-life of nalbuphine is 5 hours, and in clinical studies the duration of analgesic activity has been reported to range from 3 to 6 hours.
The opioid antagonist activity of NUBAIN (nalbuphine hydrochloride) is one-fourth as potent as nalorphine and 10 times that of pentazocine.
NUBAIN (nalbuphine hydrochloride) may produce the same degree of respiratory depression as equianalgesic doses of morphine. However, NUBAIN (nalbuphine hydrochloride) exhibits a ceiling effect such that increases in dose greater than 30 mg do not produce further respiratory depression in the absence of other CNS active medications affecting respiration.
NUBAIN (nalbuphine hydrochloride) by itself has potent opioid antagonist activity at doses equal to or lower than its analgesic dose. When administered following or concurrent with mu agonist opioid analgesics (e.g., morphine, oxymorphone, fentanyl), NUBAIN (nalbuphine hydrochloride) may partially reverse or block opioid-induced respiratory depression from the mu agonist analgesic. NUBAIN (nalbuphine hydrochloride) may precipitate withdrawal in patients dependent on opioid drugs. NUBAIN (nalbuphine hydrochloride) should be used with caution in patients who have been receiving mu opioid analgesics on a regular basis.
Last reviewed on RxList: 1/4/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Nubain Information
Report Problems to the Food and Drug Administration
Chronic Pain/Back Pain
Find tips and advances in treatment.